

Ⅲ. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表レイアウト

雑誌 (外国語)

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tamura K, Imamura CK, Takano T, et al.	CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase	J Clin Oncol	38	558-566	2020
Modi S, Saura C, Yamashita T, Tamura K et al.	DESTINY-Breast01 Investigators: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast	N Engl J Med.	382	610-621	2020
Ebata T, Yonemori K, Nishikawa T, Tamura K et al.	Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.	Oncology	98	699-705	2020
Noda-Narita S, Shimomura A, Tanabe Y, Tamura K et al.	Peripheral Neuropathy From Paclitaxel: Risk Prediction by Serum microRNAs	BMJ Support Palliat Care		doi: 10.1136/bmjspcare-2019-001900 2020	2020
Uehara T, Yoshida H, Fukuhara M, Tamura K et al.	Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients	Gynecol Oncol.	157	398-404	2020
Modi S, Park H, Murthy RK, Tamura K et al.	Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.	J Clin Oncol	38	1887-1896	2020
Iwata H, Inoue K, Kaneko K, Tamura K et al.	Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)	Jpn J Clin Oncol.	50	223. doi: 10.1093/jjco/hyz208, 2020	2020
Yoshida A, Arai Y, Hama N, Tamura K et al.	Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults.	Histopathology	76	Epub ahead of print	2020
Kato MK, Yunokawa M, Bun S, Tamura K, et al.	Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data	J Cancer Res Clin Oncol	146	1335-1341	2020
Seo T, Noguchi E, Yoshida M, Tamura K et al.	Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation	Case Rep Oncol Med	6	2518383. doi: 10.1155/2020/2518383. eCollection,	2020

Matsumoto K, Takahashi M, Sato K, <u>Tamura K.</u> et al.	A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.	Cancer Med	9	3319-3327	2020
Tsurutani J, Iwata H, Krop I, <u>Tamura K.</u> et al.	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors	Cancer Discov.	10	688-701	2020
Watanabe S, Shimomura A, Kubo T, <u>Tamura K.</u> et al.	BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma.	Mod Pathol.	33	1660-1668	2020
Sugano T, Yoshida M, Masuda M, <u>Tamura K.</u> et al.	Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma.	Br J Cancer.	122	1811-1817	2020
Tanabe Y, Shiraishi S, Hashimoto K, <u>Tamura K.</u> et al.	Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. BMC Cancer.	BMC Cancer.	20	325. doi: 10.1186/s12885-020-06834-0., 2020	2020
Smyth LM, <u>Tamura K.</u> , Oliveira M, et al	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> ^{ELT8} -Mutant, ER-Positive Metastatic Breast Cancer.	Clin Cancer Res	26	3947-3957	2020
Kawachi A, Yamashita S, Okochi-Takada E, <u>Tamura K.</u> et al	BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy	Breast Cancer Res Treat	181	323-329	2020
Mehnert JM, Bergsland E, O'Neill BH, <u>Tamura K.</u> et al	Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer	Cancer	126	3021-3030	2020
Sanchez Calle A, Yamamoto T, Kawamura Y, <u>Tamura K.</u> et al	Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers	Mol Oncol.	14	2271-2287	2020

Mizuno T, Kojima Y, Yonemori K, <u>Tamura K.</u> et al	HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenocarcinoma of the cervix	Oncol Lett.	20	38. doi: 10.3892/ol.2020.11899. Epub	2020
Hayashi N, Kumamaru H, Isozumi U, <u>Tamura K.</u> et al	Annual report of the Japanese Breast Cancer Registry for 2017 Breast Cancer.	Breast cancer	27	803-809	2020
Minami H, Ando Y, <u>Tamura K.</u> et al	Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer	Anticancer Res	40	5229-5235	2020
Watanuki R, Shimomura A, Yazaki S, <u>Tamura K.</u> et al	Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuz	Medicine (Baltimore).	18	99(38):e22331. doi: 10.1097/MD.00000000000022331	2020
Ryu S, Ohuchi M, Yagishita S, <u>Tamura K.</u> et al	Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spect	Sci Rep.	23	10(1):15535. doi: 10.1038/s41598-020-72665-5	2020
Mizuno T, Kojima Y, Yonemori K, <u>Tamura K.</u> et al	Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer	Oncol Lett	20	336. doi: 10.3892/ol.2020.12200. Epub	2020
Kondo S, Shimizu T, Koyama T, <u>Tamura K.</u> et al	First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors	Cancer Sci	7	doi: 10.1111/cas.14765. Online ahead of print	2020
Hata T, Nakamura K, Yonemori K, <u>Tamura K.</u> et al	Regulatory and Operational Challenges in Conducting Asian International Academic Trial for Expanding the Indications of Cancer Drugs	Clin Transl Sci	-	doi: 10.1111/cts.12965. Online ahead of print,	2020
Yamamoto N, Shimizu T, Yonemori K, <u>Tamura K.</u> et al	A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors	Invest New Drugs	9	doi: 10.1007/s10637-020-01055-5. Online ahead of print	2020
Yonemori K, Shimizu T, Kondo S, <u>Tamura K.</u> et al	The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study	Jpn J Clin Oncol	24	hyab013. doi: 10.1093/jco/hyab013. Online ahead of print	2021
Winer EP, Lipatov O, Im SA, <u>Tamura K.</u> et al	KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial	Lancet Oncol	4	S1470-2045(20)30754-3. doi: 10.1016/S1470-2045(20)30754-3. Online ahead of print	2021

Poveda A, Floquet A, Ledermann JA, <u>Tamura K.</u> et al	SOLO2/ENGOT-Ov21 investigator s. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial	Lancet Oncol	22	620-631	2021
---	---	--------------	----	---------	------